Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Identifieur interne : 000438 ( Main/Exploration ); précédent : 000437; suivant : 000439Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Auteurs : Francine Foss [États-Unis] ; Barbara Pro [États-Unis] ; H. Miles Prince [Australie] ; Lubomir Sokol [États-Unis] ; Dolores Caballero [Espagne] ; Steven Horwitz [États-Unis] ; Bertrand Coiffier [France]Source :
- Cancer medicine [ 2045-7634 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de survie, Antibiotiques antinéoplasiques (administration et posologie), Antibiotiques antinéoplasiques (usage thérapeutique), Depsipeptides (administration et posologie), Depsipeptides (usage thérapeutique), Humains, Lymphome T périphérique (traitement médicamenteux), Récidive tumorale locale (traitement médicamenteux), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
- MESH :
- administration et posologie : Antibiotiques antinéoplasiques, Depsipeptides.
- traitement médicamenteux : Lymphome T périphérique, Récidive tumorale locale.
- usage thérapeutique : Antibiotiques antinéoplasiques, Depsipeptides.
- Adulte, Adulte d'âge moyen, Analyse de survie, Humains, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic (administration & dosage), Antibiotics, Antineoplastic (therapeutic use), Depsipeptides (administration & dosage), Depsipeptides (therapeutic use), Humans, Lymphoma, T-Cell, Peripheral (drug therapy), Middle Aged, Neoplasm Recurrence, Local (drug therapy), Survival Analysis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibiotics, Antineoplastic, Depsipeptides.
- chemical , therapeutic use : Antibiotics, Antineoplastic, Depsipeptides.
- drug therapy : Lymphoma, T-Cell, Peripheral, Neoplasm Recurrence, Local.
- Adult, Aged, Aged, 80 and over, Humans, Middle Aged, Survival Analysis, Treatment Outcome.
Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed/refractory PTCL demonstrated an objective response rate of 25% (33/130), including 15% with confirmed/unconfirmed complete response, and a median duration of response of 28 months. In the analysis presented herein, romidepsin was shown to have similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for PTCL irrespective of the number of prior therapies.
DOI: 10.1002/cam4.939
PubMed: 27981793
Affiliations:
- Australie, Espagne, France, États-Unis
- Auvergne-Rhône-Alpes, Connecticut, Floride, Pennsylvanie, Rhône-Alpes, Victoria (État), État de New York
- Lyon, Melbourne
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001337
- to stream PubMed, to step Curation: 001315
- to stream PubMed, to step Checkpoint: 001315
- to stream Ncbi, to step Merge: 004040
- to stream Ncbi, to step Curation: 004040
- to stream Ncbi, to step Checkpoint: 004040
- to stream Main, to step Merge: 000433
- to stream Main, to step Curation: 000438
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.</title><author><name sortKey="Foss, Francine" sort="Foss, Francine" uniqKey="Foss F" first="Francine" last="Foss">Francine Foss</name><affiliation wicri:level="2"><nlm:affiliation>Yale Cancer Center, New Haven, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Yale Cancer Center, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><affiliation wicri:level="2"><nlm:affiliation>Thomas Jefferson University, Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Thomas Jefferson University, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H" last="Miles Prince">H. Miles Prince</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><affiliation wicri:level="2"><nlm:affiliation>Moffitt Cancer Center, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Moffitt Cancer Center, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Caballero, Dolores" sort="Caballero, Dolores" uniqKey="Caballero D" first="Dolores" last="Caballero">Dolores Caballero</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Salamanca, Salamanca</wicri:regionArea><wicri:noRegion>Salamanca</wicri:noRegion></affiliation></author><author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Memorial Sloan Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation wicri:level="3"><nlm:affiliation>Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27981793</idno><idno type="pmid">27981793</idno><idno type="doi">10.1002/cam4.939</idno><idno type="wicri:Area/PubMed/Corpus">001337</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001337</idno><idno type="wicri:Area/PubMed/Curation">001315</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001315</idno><idno type="wicri:Area/PubMed/Checkpoint">001315</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001315</idno><idno type="wicri:Area/Ncbi/Merge">004040</idno><idno type="wicri:Area/Ncbi/Curation">004040</idno><idno type="wicri:Area/Ncbi/Checkpoint">004040</idno><idno type="wicri:Area/Main/Merge">000433</idno><idno type="wicri:Area/Main/Curation">000438</idno><idno type="wicri:Area/Main/Exploration">000438</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.</title><author><name sortKey="Foss, Francine" sort="Foss, Francine" uniqKey="Foss F" first="Francine" last="Foss">Francine Foss</name><affiliation wicri:level="2"><nlm:affiliation>Yale Cancer Center, New Haven, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Yale Cancer Center, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><affiliation wicri:level="2"><nlm:affiliation>Thomas Jefferson University, Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Thomas Jefferson University, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H" last="Miles Prince">H. Miles Prince</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><affiliation wicri:level="2"><nlm:affiliation>Moffitt Cancer Center, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Moffitt Cancer Center, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Caballero, Dolores" sort="Caballero, Dolores" uniqKey="Caballero D" first="Dolores" last="Caballero">Dolores Caballero</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Salamanca, Salamanca</wicri:regionArea><wicri:noRegion>Salamanca</wicri:noRegion></affiliation></author><author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Memorial Sloan Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation wicri:level="3"><nlm:affiliation>Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j">Cancer medicine</title><idno type="eISSN">2045-7634</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibiotics, Antineoplastic (administration & dosage)</term><term>Antibiotics, Antineoplastic (therapeutic use)</term><term>Depsipeptides (administration & dosage)</term><term>Depsipeptides (therapeutic use)</term><term>Humans</term><term>Lymphoma, T-Cell, Peripheral (drug therapy)</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Antibiotiques antinéoplasiques (administration et posologie)</term><term>Antibiotiques antinéoplasiques (usage thérapeutique)</term><term>Depsipeptides (administration et posologie)</term><term>Depsipeptides (usage thérapeutique)</term><term>Humains</term><term>Lymphome T périphérique (traitement médicamenteux)</term><term>Récidive tumorale locale (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibiotics, Antineoplastic</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibiotics, Antineoplastic</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antibiotiques antinéoplasiques</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, T-Cell, Peripheral</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphome T périphérique</term><term>Récidive tumorale locale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibiotiques antinéoplasiques</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Middle Aged</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Humains</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed/refractory PTCL demonstrated an objective response rate of 25% (33/130), including 15% with confirmed/unconfirmed complete response, and a median duration of response of 28 months. In the analysis presented herein, romidepsin was shown to have similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for PTCL irrespective of the number of prior therapies.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Espagne</li><li>France</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Connecticut</li><li>Floride</li><li>Pennsylvanie</li><li>Rhône-Alpes</li><li>Victoria (État)</li><li>État de New York</li></region><settlement><li>Lyon</li><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Foss, Francine" sort="Foss, Francine" uniqKey="Foss F" first="Francine" last="Foss">Francine Foss</name></region><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H" last="Miles Prince">H. Miles Prince</name></region></country><country name="Espagne"><noRegion><name sortKey="Caballero, Dolores" sort="Caballero, Dolores" uniqKey="Caballero D" first="Dolores" last="Caballero">Dolores Caballero</name></noRegion></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000438 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000438 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27981793
|texte= Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27981793" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |